140 related articles for article (PubMed ID: 38461569)
1. Oncological outcomes of patients with oligometastatic oesophagogastric cancer.
Down B; Lakunina S; Maynard N; Markar SR; Gordon-Weeks A
Eur J Surg Oncol; 2024 Apr; 50(4):108231. PubMed ID: 38461569
[TBL] [Abstract][Full Text] [Related]
2. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese TE; van Laarhoven HWM; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds J; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshof MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs CT; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen G; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Hillegersberg R; van Rossum PSN;
Eur J Cancer; 2023 May; 185():28-39. PubMed ID: 36947929
[TBL] [Abstract][Full Text] [Related]
3. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Kroese TE; van Hillegersberg R; Schoppmann S; Deseyne PRAJ; Nafteux P; Obermannova R; Nordsmark M; Pfeiffer P; Hawkins MA; Smyth E; Markar S; Hanna GB; Cheong E; Chaudry A; Elme A; Adenis A; Piessen G; Gani C; Bruns CJ; Moehler M; Liakakos T; Reynolds J; Morganti A; Rosati R; Castoro C; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; Jeene P; van Sandick JW; Muijs C; Slingerland M; Nieuwenhuijzen G; Wijnhoven B; Beerepoot LV; Kolodziejczyk P; Polkowski WP; Alsina M; Pera M; Kanonnikoff TF; Nilsson M; Guckenberger M; Monig S; Wagner D; Wyrwicz L; Berbee M; Gockel I; Lordick F; Griffiths EA; Verheij M; van Rossum PSN; van Laarhoven HWM;
Eur J Cancer; 2022 Mar; 164():18-29. PubMed ID: 35134666
[TBL] [Abstract][Full Text] [Related]
4. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
5. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
10. Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence.
Weiss ARR; Donlon NE; Schlitt HJ; Hackl C
Langenbecks Arch Surg; 2022 May; 407(3):947-955. PubMed ID: 34860291
[TBL] [Abstract][Full Text] [Related]
11. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
12. Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.
Mihai A; Mu Y; Armstrong J; Dunne M; Beriwal S; Rock L; Thirion P; Heron DE; Bird BH; Westrup J; Murphy CG; Huq MS; McDermott R
J Radiosurg SBRT; 2017; 5(1):43-53. PubMed ID: 29296462
[TBL] [Abstract][Full Text] [Related]
13. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
Runkel M; Verst R; Spiegelberg J; Fichtner-Feigl S; Hoeppner J; Glatz T
BMC Surg; 2021 Jan; 21(1):35. PubMed ID: 33435947
[TBL] [Abstract][Full Text] [Related]
14. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
15. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
Wright CM; Lee DY; Shimunov D; Carmona R; Barsky AR; Sun L; Cohen RB; Bauml JM; Brody RM; Basu D; Rassekh CH; Chalian AA; Newman JG; Rajasekaran K; Weinstein GS; Lukens JN; Lin A; Swisher-McClure S
Oral Oncol; 2021 Oct; 121():105509. PubMed ID: 34474270
[TBL] [Abstract][Full Text] [Related]
16. Modeling growth kinetics and statistical distribution of oligometastases.
Withers HR; Lee SP
Semin Radiat Oncol; 2006 Apr; 16(2):111-9. PubMed ID: 16564446
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
18. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
Haj Mohammad N; Bernards N; van Putten M; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2017 Jun; 78():28-36. PubMed ID: 28412586
[TBL] [Abstract][Full Text] [Related]
19. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
[TBL] [Abstract][Full Text] [Related]
20. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.
Kroese TE; Buijs GS; Burger MDL; Ruurda JP; Mook S; Brosens LAA; van Rossum PSN; van Hillegersberg R
Ann Surg Oncol; 2022 Aug; 29(8):4848-4857. PubMed ID: 35381938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
